

- **Name:** Hyeon-Su Im
 - **Current Position & Affiliation:** Assistant Professor, Division of Hematology and Oncology, Department of Internal Medicine, Ulsan University Hospital
 - **Country:** Korea
-

• Educational Background:

Bachelor's Degree in Medicine, Hanyang University, College of Medicine, Seoul, South Korea

Master's Degree in Medicine, Ulsan University, College of Medicine, Ulsan, South Korea

Ph.D. Candidate in Medicine (Coursework completed), Ulsan University, College of Medicine, Ulsan, South Korea

• Professional Experience:

Intern, Asan medical center

Internal Medicine Resident, Asan medical center

Clinical fellowship, Asan medical center

Clinical Assistant Professor, Ulsan University Hospital

Assistant Professor, Ulsan University Hospital

• Professional Organizations:

The Korean Association of Internal Medicine

The Korean Cancer Association

Korean Society of Medical Oncology

Korean Cancer Study Group

The Korean Gastric Cancer Association

American Society of Clinical Oncology

European Society of Medical Oncology

• Main Scientific Publications:

1. Im HS, Lee I, Kim S, Lee JS, Kim JH, Moon JY, Park BK, Lee KH, Lee MA, Han S, Hong Y, Kim H, Cheon J, Koh SJ. Experience and perspectives of end-of-life care discussion and physician orders for life-sustaining treatment of Korea (POLST-K): a cross-sectional study. BMC Med Ethics. 2023 Mar 7;24(1):18. doi: 10.1186/s12910-023-00897-x. PMID: 36882795; PMCID: PMC9993746.

2. Jeong H, Im HS, Kim W, Lee JS, Song SY, Song JS, Cho KJ, Chung HW, Lee MH, Kim JE, Ahn JH. Demographics, Changes in Treatment Patterns, and Outcomes of Bone and Soft Tissue Sarcomas in Korea-A Sarcoma-Specific, Institutional Registry-Based Analysis. *Cancer Manag Res*. 2021 Nov 24;13:8795-8802. doi: 10.2147/CMAR.S337606. PMID: 34853534; PMCID: PMC8627857.
3. Kim EJ, Im HS, Lee J, Cho EH, Kim YH, Kim HR, Kim JH, Park SR. Genome-wide and size-based cell-free DNA indices as predictive biomarkers for locally advanced esophageal squamous cell carcinoma treated with preoperative or definitive chemoradiotherapy. *Curr Probl Cancer*. 2021 Jun;45(3):100685. doi: 10.1016/j.currprobcancer.2020.100685. Epub 2020 Nov 28. PMID: 33342577.
4. Kim HD, Im HS, Kim JH, Jeong H, Yoon SK, Park I, Lee JL. Use of Gemcitabine plus Carboplatin is Associated with Poor Outcomes in Urothelial Carcinoma Patients with Chronic Kidney Disease Stage 4-5. *Cancer Res Treat*. 2021 Oct;53(4):1166-1173. doi: 10.4143/crt.2021.091. Epub 2021 Mar 4. PMID: 33677847; PMCID: PMC8524029.
5. Oh CR, Kong SY, Im HS, Kim HJ, Kim MK, Yoon KA, Cho EH, Jang JH, Lee J, Kang J, Park SR, Ryoo BY. Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib. *BMC Cancer*. 2019 Apr 1;19(1):292. doi: 10.1186/s12885-019-5483-x. PMID: 30935424; PMCID: PMC6444867.
6. Yoo C, Im HS, Kim KP, Oh DY, Lee KH, Chon HJ, Kim JH, Kang M, Kim I, Lee GJ, Oh SY, Choi Y, Choi HJ, Kim ST, Park JO, Ryoo BY. Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group. *Ther Adv Med Oncol*. 2019 Aug 23;11:1758835919871126. doi: 10.1177/1758835919871126. PMID: 31489036; PMCID: PMC6710683.